Ten-Year APHINITY Data Show Genentech's Perjeta-based Regimen Reduced the Risk of Death by 17% in HER2-Positive Early-Stage Brea

• click to rate

  Posted by Two Blokes Tue at 7:15 AM - Filed in Stock - 2 views
  
  SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), the Breast International Group (BIG), Institut Jules Bordet Clinical Trials Support Unit and Frontier Science Foundation, announced today statistically significant final overall survival (OS) results from the Phase III APHINITY study in people with human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer. After ten years, the risk of death was reduced by 1.